Unpacking the GLP-1 Gold Rush
We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to headline-grabbing agents of a global weight-loss revolution. But the science, strategy, and scale behind these therapies are far more complex than the public narrative suggests. This exclusive eBook, The GLP-1 Gold […]
Your Weight Matters Region
Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to meet you wherever you are in your journey—whether you’re just starting to explore your options or want to better understand your health.Each event features a physician, mental health professional and […]
CagriSema: Weight Loss in Overweight or Obese Adults
This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults who are overweight or obese. The study randomized over 3400 participants into groups receiving the combination therapy, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle interventions. Results demonstrated significant and clinically relevant body-weight […]
GLP-1 Agonists: Uses, Mechanism, and Side Effects
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these injectable drugs mimic a natural hormone to regulate blood sugar, slow digestion, and increase feelings of fullness, leading to potential weight loss. The source lists various approved GLP-1 agonists and their typical administration frequencies, […]
Novo is not dead yet! Novo Nordisk’s experimental drug results in up to 24% weight loss
June 20 (Reuters) – Novo Nordisk (NOVOb.CO) On Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines – Other Posters and Talks
🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”Presenter: Dr. Lloyd L. Tran (CEO)Date & Time: June 20, 2025 – oral session (specific time TBD at conference)Poster:Title: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial […]
ADA (American Diabetes Association) June 20-24 Obesity Medicines – Lilly Posters and Talks
Lilly Orgorglipron Orforglipron is a novel, oral, non-peptide GLP‑1 receptor agonist, and the ACHIEVE‑1 Phase III data demonstrated efficacy and tolerability comparable to existing injectables Oral Presentation – Lilly will feature its oral GLP‑1 candidate, orforglipron, with topline results from its Phase III ACHIEVE‑1 trial showing positive safety, glycemic control, and weight loss (~8 % at 40 weeks). This […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines Novo Nordisk Posters and Talks
Novo CagriSema CagriSema is an investigational medication being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It is a fixed-dose combination of two drugs: Cagrilintide: An amylin analog that helps regulate appetite and reduce food intake Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that improves blood sugar control and promotes weight loss. CagriSema is designed […]
Tirzepatide for Weight Loss in Non-Diabetics: A Meta-Analysis
Kommu S, Sharma PP, Gabor RM. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obes Rev. 2025 Jun 13:e13961. doi: 10.1111/obr.13961. Epub ahead of print. PMID: 40510020. This article presents a systematic review and meta-analysis on the efficacy and safety of tirzepatide for weight loss in […]
The Vibrating Belt Machine
I heard the discourse between Laraine and Christopher last night on the Downsized and I came across this article in the Business Insider today, and I just had to pass it on… Working out without working hard – the rise of Ozempic has Americans chasing dubious muscle-building miracles by Emily Steward June 12, 2025 in […]